NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma
- Active, not recruiting
- Dec 2, 2020
- 3 min read
Updated: Feb 20, 2024
MagnetisMM-3
NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma
Relapsed & Refractory Multiple Myeloma
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Sponsor
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04649359
Official Title: MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
First Posted : December 2, 2020
Click here for details on Clinicaltrials.gov
Elranatamab (Code C146860)
Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135
B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135
BCMA x CD3 Bispecific Antibody PF-06863135
BCMA-CD3 Bispecific Ab PF-06863135
Elranatamab
ELRANATAMAB
PF 06863135
PF-06863135
PF06863135
RN 613
RN-613
RN613
Nature Medicine
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Meeting: 2022 ASCO Annual Meeting - Session Type: Oral Abstract Session - Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia - Track: Hematologic Malignancies - Sub Track: Hematologic Malignancies - Clinical Trial Registration Number: NCT04649359
Abstract#: 8006 - Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
ABSTRACTS & PRESENTATIONS
2022 ASCO ANNUAL MEETING - June 3-7, 2022 - McCormick Place, Chicago, IL - Hybrid Meeting
2022 ASCO Annual Meeting - Oral Abstract Session
- Florida: Miami Cancer Institute
- Georgia: Emory University Atlanta
- Iowa: University of Iowa Iowa city
- Massachusetts: Massachusetts General Hospital Boston
- New Jersey: Hackensack University Medical Center
- New York: Roswell Park Cancer Institute Buffalo
- New York: Memorial Sloan-Kettering Cancer Center New York
- New York: New York Presbyterian / Weill Cornell Medical College New York
- Pennsylvania: Fox Chase Cancer Center Philadelphia
- Texas: Baylor University Medical Center Dallas
Locations
United States, California
United States, Florida
United States, Georgia
United States, Illinois
United States, Indiana
United States, Iowa
United States, Kentucky
United States, Louisiana
United States, Massachusetts
United States, New Jersey
United States, New York
United States, Pennsylvania
United States, South Carolina
United States, Texas
Canada, Alberta
Canada, Quebec
Europe
United Kingdom
France
Germany
Spain
Belgium
Poland
Asia
Japan
Australia, Victoria
RELATED POSTS
MagnetisMM-1
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma - MagnetisMM-1
MAGNETISMM-2
NCT04798586: Phase 1: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma - MAGNETISMM-2
MagnetisMM-4
NCT05090566: Phase 2: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM - MagnetisMM-4
MagnetisMM-5
NCT05020236: Phase 3: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex - MagnetisMM-5
MagnetisMM-7
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
MagnetisMM-8
NCT05228470: Phase 2: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM - MagnetisMM-8
MagnetisMM-9
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)